Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Abstract: The present invention concerns a method for preparing a composite material comprising electrically conductive or semiconductive nano-objects of elongate shape and an electrically conductive polymer matrix, said method comprising a step consisting in electrochemically deposing said matrix on said nano-objects using a pulsed galvanostatic technique. The present invention also concerns the composite material thus obtained and uses thereof.

Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Abstract: The invention relates to a method for producing an anion-exchange polymer material having an IPN or semi-IPN structure, said method consisting in: (A) preparing a homogeneous reaction solution containing, in a suitable organic solvent, (a) at least one organic polymer bearing reactive halogen groups, (b) at least one tertiary diamine, (c) at least one monomer comprising an ethylenic unsaturation polymerizable by free radical polymerization, (d) optionally at least one cross-linking agent including at least two ethylenic unsaturations polymerizable by free radical polymerization, and e) at least one free radical polymerization initiator; and (B) heating the prepared solution to a temperature and for a duration that are sufficient to allow both a nucleophilic substitution reaction between components (a) and (b) and a free radical copolymerization reaction of components (c) and optionally (d) initiated by component (e).

Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at one symptom of an ocular condition, such as glaucoma.

Abstract: Disclosed is a sample handling assembly facilitating a sample holding cell used for XRD analysis. The assembly holds the sample cell upright during sample loading and analysis phases. The sample handling assembly is vibrated, partly by a tuning fork, to allow the powder to flow into the sample cell. After the XRD analysis, a rotating arm holding the sample cell is rotated 180° to orient the sample cell completely upside down so that the sample can be emptied. Also disclosed are jets of air that are pulsed onto the sample cell, and/or into the sample cell funnel-tube assembly, to shake and clean the components.

Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce at least one symptom of an ocular condition, such as glaucoma.

Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Abstract: Disclosed is a sample handling assembly facilitating a sample holding cell used for XRD analysis. The assembly holds the sample cell upright during sample loading and analysis phases. The sample handling assembly is vibrated, partly by a tuning fork, to allow the powder to flow into the sample cell. After the XRD analysis, a rotating arm holding the sample cell is rotated 180° to orient the sample cell completely upside down so that the sample can be emptied. Also disclosed are jets of air that are pulsed onto the sample cell, and/or into the sample cell funnel-tube assembly, to shake and clean the components.

Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Abstract: The invention relates to a method for producing an anion-exchange polymer material having an IPN or semi-IPN structure, said method consisting in: (A) preparing a homogeneous reaction solution containing, in a suitable organic solvent, (a) at least one organic polymer bearing reactive halogen groups, (b) at least one tertiary diamine, (c) at least one monomer comprising an ethylenic unsaturation polymerizable by free radical polymerization, (d) optionally at least one cross-linking agent including at least two ethylenic unsaturations polymerizable by free radical polymerization, and e) at least one free radical polymerization initiator; and (B) heating the prepared solution to a temperature and for a duration that are sufficient to allow both a nucleophilic substitution reaction between components (a) and (b) and a free radical copolymerization reaction of components (c) and optionally (d) initiated by component (e).

Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Abstract: The invention relates to a method for producing an anion-exchange polymer material having an IPN or semi-IPN structure, said method consisting in: (A) preparing a homogeneous reaction solution containing, in a suitable organic solvent, (a) at least one organic polymer bearing reactive halogen groups, (b) at least one tertiary diamine, (c) at least one monomer comprising an ethylenic unsaturation polymerizable by free radical polymerization, (d) optionally at least one cross-linking agent including at least two ethylenic unsaturations polymerizable by free radical polymerization, and e) at least one free radical polymerization initiator; and (B) heating the prepared solution to a temperature and for a duration that are sufficient to allow both a nucleophilic substitution reaction between components (a) and (b) and a free radical copolymerization reaction of components (c) and optionally (d) initiated by component (e).

Abstract: Biocompatible intraocular microspheres can include an active agent and a biodegradable polymer that is effective to facilitate release of the active agent into the vitreous of an eye for an extended period of time. The therapeutic agent of the microsphere can be associated with a biodegradable polymer matrix and can be made by crystallizing the active agent in the matrix. the resulting biodegradable microspheres can be placed into an eye to treat or reduce the occurrence of one or more ocular conditions.

Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Abstract: Sample cell assemblies containing and holding powdered, granular, paste, or liquid samples are assembled and manufactured in a way that allows them to be inexpensive enough to be disposable and configured to be attached to a fork member for providing shaking or vibrating movement to the samples for X-ray Diffraction and X-ray Fluorescence testing. The sample cell assemblies include the usage of double-sided adhesive films and spacer for sealing the component of the sample cell assemblies, and latches as locking means for locking and unlocking the cell assemblies.

Abstract: Biocompatible intraocular microspheres include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the microspheres can be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The microspheres can be placed into an eye to treat or reduce the occurrence of one or more ocular conditions.

Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the ploymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Abstract: The present invention concerns a method for preparing a composite material comprising electrically conductive or semiconductive nano-objects of elongate shape and an electrically conductive polymer matrix, said method comprising a step consisting in electrochemically deposing said matrix on said nano-objects using a pulsed galvanostatic technique. The present invention also concerns the composite material thus obtained and uses thereof.